News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Endologix Inc. Reports 20% Revenue Growth for the Third Quarter 2012
October 26, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
IRVINE, Calif., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Drug pricing
White House Strikes GLP-1 Pricing Deal With Lilly, Novo
November 6, 2025
·
3 min read
·
Annalee Armstrong
Earnings
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing
November 6, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics
November 6, 2025
·
2 min read
·
Tristan Manalac
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
November 6, 2025
·
2 min read
·
Tristan Manalac